CP-25 ameliorates dysfunction in the M3R-IP3R-Ca2+-AQP5 signaling pathway by inhibiting ERS in primary Sjögren's syndrome
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.115804 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Lei Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Science, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education; Institute o…. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Receptor, Muscarinic M3, Endoplasmic Reticulum Stress, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Anhui Medical University, National Natural Science Foundation of China, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Primary Sjögren's syndrome (pSS) is an autoimmune disease with incompletely elucidated pathological mechanisms and a current lack of effective therapeutic agents. CP-25, a structurally modified derivative of paeoniflorin, demonstrates significant therapeutic effects in experimental Sjögren's syndrome (ESS) mouse models; however, its underlying mechanism remains elusive. In this study, we constructed an ESS mouse model induced by autoantigen immunization to explore the biological effects of CP-25 on pSS and its potential mechanisms. The study first revealed the overactivation of endoplasmic reticulum stress (ERS) and the impaired function of M3R-IP3R-Ca2+-AQP5 signaling pathway in human labial gland tissue. Critically, inhibiting ERS (using 4-PBA) was found to directly ameliorate the impaired M3R-IP3R-Ca2+-AQP5 signaling pathway function, as evidenced by normalized M3R expression, restored IP3R and AQP5 levels, and enhanced intracellular Ca2+ intensity in IFNα-stimulated HSGECs, resulting in significantly increased salivary flow rate and reduced salivary gland inflammation in vivo. Furthermore, CP-25 exerted its therapeutic effect by upregulating the M3R-IP3R-Ca2+-AQP5 signaling pathway function, regulating M3R membrane expression, and critically inhibiting ERS. Crucially, the beneficial effects of CP-25 on both ERS suppression and pathway restoration were demonstrated to be mechanistically dependent on disrupting the pathological interaction between the key ERS chaperone GRP78 and the IP3R calcium channel. In summary, impaired M3R-IP3R-Ca2+-AQP5 signaling contributes to pSS pathogenesis. CP-25 treats pSS by restoring this pathway through regulating M3R membrane expression, inhibiting ERS, reducing apoptosis, and decreasing GRP78-IP3R co-expression in HSGECs. This study provides experimental support for CP-25's mechanism and potential clinical application in pSS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Science, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education; Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, Anhui…
- Guangzhou Hanfang Pharmaceutical Co., Ltd., 510240, Guangdong, China.
- Department of Ophthalmology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui, China. Electronic address: 15056967187@163.com.
- Department of Pharmacy, Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui, China.. Electronic address: wangyuanyuan@ahmu.edu.cn.
Förderung
- Anhui Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
Zitieren
APA
Huang, L., Zhang, Y., Kuang, F., Xi, Q., Chen, Y., Xu, W., Cai, H., Mao, Y., Wang, J., Wang, Y., & Wu, H. (2026). CP-25 ameliorates dysfunction in the M3R-IP3R-Ca2+-AQP5 signaling pathway by inhibiting ERS in primary Sjögren's syndrome. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115804
Vancouver
Huang L, Zhang Y, Kuang F, Xi Q, Chen Y, Xu W, et al. CP-25 ameliorates dysfunction in the M3R-IP3R-Ca2+-AQP5 signaling pathway by inhibiting ERS in primary Sjögren's syndrome. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.115804
BibTeX
@article{Huang2026,
author = {Huang, Lei and Zhang, Yunxin and Kuang, Fuxue and Xi, Qi and Chen, Yun and Xu, Wendong and Cai, Hongfei and Mao, Yukang and Wang, Jing and Wang, Yuanyuan and Wu, Huaxun},
title = {CP-25 ameliorates dysfunction in the M3R-IP3R-Ca2+-AQP5 signaling pathway by inhibiting ERS in primary Sjögren's syndrome},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.115804}
}
EUVIMED